[1]张佳慧,陈晓隆.糖尿病视网膜病变的诊断和治疗：2016-2018年最新研究进展[J].眼科新进展,2018,38(12):1185-1190.[doi:10.13389/j.cnki.rao.2018.0280]
　ZHANG Jia-Hui,CHEN Xiao-Long.Diagnosis and treatment of diabetic retinopathy：the latest research progress in the year of 2016-2018[J].Recent Advances in Ophthalmology,2018,38(12):1185-1190.[doi:10.13389/j.cnki.rao.2018.0280]
点击复制

糖尿病视网膜病变的诊断和治疗：2016-2018年最新研究进展/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
38卷
期数:
2018年12期
页码:
1185-1190
栏目:
文献综述
出版日期:
2018-12-05

文章信息/Info

Title:
Diagnosis and treatment of diabetic retinopathy：the latest research progress in the year of 2016-2018
作者:
张佳慧; 陈晓隆
110001　辽宁省沈阳市，中国医科大学附属盛京医院眼科
Author(s):
ZHANG Jia-Hui; CHEN Xiao-Long
Department of Ophthalmology，Shengjing Hospital of China Medical University，Shenyang 110001，Liaoning Province，China
关键词:
糖尿病视网膜病变; 诊断; 治疗; 最新研究进展
Keywords:
diabetic retinopathy; diagnosis; treatment; latest research progress
分类号:
R774.1
DOI:
10.13389/j.cnki.rao.2018.0280
文献标志码:
A
摘要:
糖尿病视网膜病变（diabetic retinopathy，DR）是糖尿病的一种威胁视力的并发症，是致盲的主要原因。DR发病机制复杂，目前尚不明确。大量的证据使人们意识到DR不仅是一种血管疾病，而且是一种神经退行性疾病。目前针对DR治疗方案效果有限，DR的早期诊断、防治至关重要。本文就近两年DR的诊断、治疗的最新研究进展及新的治疗靶点进行综述。
Abstract:
Diabetic retinopathy （DR） is a sight-threatening complication of diabetes and the leading cause of vision loss.The pathogenesis of DR is complex and not clear.DR traditionally has been considered as a microvascular disease；however，new evidence suggests that it is also a neurodegenerative disease.The effectiveness of current treatments for DR is limited.Therefore，a multidisciplinary approach and novel strategies to detect，prevent and treat DR in the early stages are needed.This review provides an update on the novel developments in DR diagnosis，treatment and new therapeutic targets in the nearly two years.

参考文献/References:

［1］　THOMAS R L，DUNSTAN F，LUZIO S D，ROY C S，HALE S L，NORTH R V，et al.Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the Diabetic Retinopathy Screening Service for Wales：retrospective analysis［J］.BMJ，2012，344：e874.
［2］　LEE R，WONG T Y，SABANAYAGAM C.Epidemiology of diabetic retinopathy，diabetic macular edema and related vision loss［J］.Eye Vis，2015，2：17.
［3］　ZENG J，CHEN B.Epigenetic mechanisms in the pathogenesis of diabetic retinopathy［J］.Ophthalmologica，2014，232（1）：1-9.
［4］　SIMO R，HERNANDEZ C.Neurodegeneration in the diabetic eye：new insights and therapeutic perspectives［J］.Trends Endocrinol Metab，2014，25（1）：23-33.
［5］　BARBER A J.Diabetic retinopathy：recent advances towards understanding neurodegeneration and vision loss［J］.Sci China Life Sci，2015，58（6）：541-549.
［6］　SIMO R，HERNANDEZ C.Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence［J］.Prog Retin Eye Res，2015，48：160-180.
［7］　WANG S，ZUO Y，WANG N，TONG B.Fundus fluorescence angiography in diagnosing diabetic retinopathy［J］.Pak J Med Sci，2017，33（6）：1328-1332.
［8］　WANG N L.Neurodegeneration in diabetic retinopathy：current concepts and therapeutic implications［J］.Chin Med J，2016，129（24）：3001-3003.
［9］　KASHANI A H，CHEN C L，GAHM J K，ZHENG F，RICHTER G M，ROSENFELD P J，et al.Optical coherence tomography angiography：a comprehensive review of current methods and clinical applications［J］.Prog Retin Eye Res，2017，60：66-100.
［10］　BANDELLO F，CORBELLI E，CARNEVALI A，PIERRO L，QUERQUES G.Optical coherence tomography angiography of diabetic retinopathy［J］.Dev Ophthalmol，2016，56：107-112.
［11］　SILVA P S，CAVALLERANO J D，HADDAD N M，KWAK H，DYER K H，OMAR A F，et al.Peripheral lesions identified on ultrawide field imaging predict increased risk of diabetic retinopathy progression over 4 years［J］.Ophthalmology，2015，122（5）：949-956.
［12］　MAI G Y，LU J，LI M，LIU R Y，CAO D.Clinical application of ultra-widefield fluorescein angiography［J］.Chin J Pract Ophthalmol，2017，35（2）：167-170.
麦桂英，卢晶，李梅，刘入源，曹迪.超广角荧光素眼底血管造影的临床应用［J］.中国实用眼科杂志，2017，35（2）:167-170.
［13］　ABBAS Q，FONDON I，SARMIENTO A，JIMENEZ S，ALEMANY P.Automatic recognition of severity level for diagnosis of diabetic retinopathy using deep visual features［J］.Med Biol Eng Comput，2017，55（11）：1959-1974.
［14］　CHATZIRALLI I，SERGENTANIS T N，CROSBY-NWAOBI R，WINKLEY K，ELEFTHERIADIS H，ISMAIL K，et al.Model for risk-based screening of diabetic retinopathy in people with newly-diagnosed type 2 diabetes mellitus［J］.Invest Ophthalmol Vis Sci，2017，58（6）：99-105.
［15］　PARK Y G，ROH Y J.New diagnostic and therapeutic approaches for preventing the progression of diabetic retinopathy［J］.J Diabetes Res，2016，2016：1753584.
［16］　SUBASH M，COMYN O，SAMY A，QATARNEH D，ANTONA-KIS S，MEHAT M，et al.The effect of multispot laser panretinal photocoagulation on retinal sensitivity and driving eligibility in patients with diabetic retinopathy［J］.JAMA Ophthalmol，2016，134（6）：666-672.
［17］　STEWART M W.Anti-VEGF therapy for diabetic macular edema［J］.Curr Diab Rep，2014，14（8）：510.
［18］　WELLS J A，GLASSMAN A R，AYALA A R，JAMPOL L M，BRESSLER N M，BRESSLER S B，et al.Aflibercept，bevacizumab，or ranibizumab for diabetic macular edema：two-year results from a comparative effectiveness randomized clinical trial［J］.Ophthalmology，2016，123（6）：1351-1359.
［19］　SAMEEN M，KHAN M S，MUKHTAR A，YAQUB M A，ISHAQ M.Efficacy of intravitreal bevacizumab combined with pan retinal photocoagulation versus panretinal photocoagulation alone in treatment of proliferative diabetic retinopathy［J］.Pak J Med Sci，2017，33（1）：142-145.
［20］　FAN S J，CAI C M，HUANG H B，LIANG G.Effects and mechanism of anti-VEGF assisted PPV in the treatment of proliferative retinopathy［J］.Int Eye Sci，2017，17（10）：1908-1911.
范思均，蔡春梅，黄厚斌，梁歌.抗VEGF辅助PPV治疗增生性糖尿病视网膜病变的效果及作用机制分析［J］.国际眼科杂志，2017，17（10）：1908-1911.
［21］　OELLERS P，MAHMOUD T H.Surgery for proliferative diabetic retinopathy：new tips and tricks［J］.J Ophthalmic Vis Res，2016，11（1）：93-99.
［22］　WEI Q，ZHANG T，JIANG R，CHANG Q，ZHANG Y，HUANG X，et al.Vitreous fibronectin and fibrinogen expression increased in eyes with proliferative diabetic retinopathy after intravitreal anti-VEGF therapy［J］.Invest Ophthalmol Vis Sci，2017，58（13）：5783-5791.
［23］　BOLINGER M T，ANTONETTI D A.Moving past anti-VEGF：novel therapies for treating diabetic retinopathy［J］.Int J Mol Sci，2016，17（9）：1498.
［24］　PULIAFITO C A，COUSINS S W，BACHARACH J，GONZALEZ V H，HOLEKAMP N M，MERRILL P T，et al.Forming a consensus：data and guidance for physicians treating diabetic macular edema［J］.Ophthalmic Surg Lasers Imaging Retina，2016，47（4 Suppl）：S4-4S15.
［25］　HUSSAIN R M，CIULLA T A.Treatment strategies for refractory diabetic macular edema：switching anti-VEGF treatments，adopting corticosteroid-based treatments，and combination therapy［J］.Expert Opin Biol Ther，2016，16（3）：365-374.
［26］　TAKAMURA Y，SHIMURA M，KATOME T，SOMEYA H，SUGIMOTO M，HIRANO T，et al.Effect of intravitreal triamcinolone acetonide injection at the end of vitrectomy for vitreous haemorrhage related to proliferative diabetic retinopathy［J］.Br J Ophthalmol，2018,102(10):1351-1357.
［27］　SHARMA T，FONG A，LAI T Y，LEE V，DAS S，LAM D.Surgical treatment for diabetic vitreoretinal diseases：a review［J］.Clin Exp Ophthalmol，2016，44（4）：340-354.
［28］　CRIM N，VELEZ-MONTOYA R，MORALES-CANTON V.Surgical versus medical treatment for diabetic macular edema：a review［J］.Med Hypothesis Discov Innov Ophthalmol，2017，6（4）：136-142.
［29］　BERROCAL M H，ACABA L A，ACABA A.Surgery for diabetic eye complications［J］.Curr Diab Rep，2016，16（10）：99.
［30］　HUANG W，BAO Q，JIN，LIAN F.Compound danshen dripping pill for treating nonproliferative diabetic retinopathy：a meta-analysis of 13 randomized controlled trials［J］.Evid Based Compl Alternat Med，2017，2017：4848076.
［31］　BEHL T，KOTWANI A.Chinese herbal drugs for the treatment of diabetic retinopathy［J］.J Pharm Pharmacol，2017，69（3）：223-235.
［32］　LI W，WEBSTER K A，LEBLANC M E，TIAN H.Secretogranin Ⅲ：a diabetic retinopathy-selective angiogenic factor［J］.Cell Mol Life Sci，2018，75（4）：635-647.
［33］　LEBLANC M E，WANG W，CHEN X，CABEROY N B，GUO F，SHEN C，et al.Secretogranin Ⅲ as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy［J］.J Exp Med，2017，214（4）：1029-1047.
［34］　CAMPOCHIARO P A，PETERS K G.Targeting Tie2 for treatment of diabetic retinopathy and diabetic macular edema［J］.Curr Diab Rep，2016，16（12）：126.
［35］　CAMPOCHIARO P A，SOPHIE R，TOLENTINO M，MILLER D M，BROWNING D，BOYER D S，et al.Treatment of diabetic macular edema with an inhibitor of vascular endothelial-protein tyrosine phosphatase that activates Tie2［J］.Ophthalmology，2015，122（3）：545-554.
［36］　HERNANDEZ C，BOGDANOV P，CORRALIZA L，GARCIARA-MIREZ M，SOLA-ADELL C，ARRANZ J A，et al.Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes［J］.Diabetes，2016，65（1）：172-187.
［37］　CAI X，LI J，WANG M，SHE M，TANG Y，LI J，et al.GLP-1 treatment improves diabetic retinopathy by alleviating autophagy through GLP-1R-ERK1/2-HDAC6 signaling pathway［J］.Int J Med Sci，2017，14（12）：1203-1212.
［38］　DELIYANTI D，ALRASHDI S F，TAN S M，MEYER C，WARD K W，de HAAN JB，et al.Nrf2 activation is a potential therapeutic approach to attenuate diabetic retinopathy［J］.Invest Ophthalmol Vis Sci，2018，59（2）：815-825.
［39］　ARIMA M，CUI D，KIMURA T，SONODA K H，ISHIBASHI T，MATSUDA S，et al.Basigin can be a therapeutic target to restore the retinal vascular barrier function in the mouse model of diabetic retinopathy［J］.Sci Rep，2016，6：38445.
［40］　AL KAHTANI E，XU Z，AL RASHAED S，WU L，MAHALE A，TIAN J，et al.Vitreous levels of placental growth factor correlate with activity of proliferative diabetic retinopathy and are not influenced by bevacizumab treatment［J］.Eye，2017，31（4）：529-536.
［41］　SZABADFI K，REGLODI D，SZABO A，SZALONTAI B，VALAS-EK A，SETALO G J，et al.Pituitary adenylate cyclase activating polypeptide，a potential therapeutic agent for diabetic retinopathy in rats：focus on the vertical information processing pathway［J］.Neurotox Res，2016，29（3）：432-446.
［42］　PARK S S.Cell therapy applications for retinal vascular diseases：diabetic retinopathy and retinal vein occlusion［J］.Invest Ophthalmol Vis Sci，2016，57（5）：ORSFj1-1ORSFj10.
［43］　KRAMEROV A A，LJUBIMOV A V.Stem cell therapies in the treatment of diabetic retinopathy and keratopathy［J］.Exp Biol Med，2016，241（6）：559-568.
［44］　FIORI A，TERLIZZI V，KREMER H，GEBAUER J，HAMMES H P，HARMSEN M C，et al.Mesenchymal stromal/stem cells as potential therapy in diabetic retinopathy［J］.Immunobiology，2018,［Epub ahead of print］.
［45］　WANG J H，LING D，TU L，VAN WIJNGAARDEN P，DUSTING G J，LIU G S.Gene therapy for diabetic retinopathy：Are we ready to make the leap from bench to bedside?［J］.Pharmacol Ther，2017，173：1-18.
［46］　GONG Y，CHANG Z P，REN R T，WEI S H，ZHOU H F，CHEN X F，et al.Protective effects of adeno-associated virus mediated brain-derived neurotrophic factor expression on retinal ganglion cells in diabetic rats［J］.Cell Mol Neurobiol，2012，32（3）：467-475.
［47］　ADHI M，CASHMAN S M，KUMAR-SINGH R.Adeno-associated virus mediated delivery of a non-membrane targeted human soluble CD59 attenuates some aspects of diabetic retinopathy in mice［J］.PLoS One，2013，8（10）：e79661.
［48］　GONG Q，XIE J，LIU Y，LI Y，SU G.Differentially Expressed micrornas in the development of early diabetic retinopathy［J］.J Diabetes Res，2017，2017：4727942.
［49］　MITRA R N，NICHOLS C A，GUO J，MAKKIA R，COOPER M J，NAASH M I，et al.Nanoparticle-mediated miR200-b delivery for the treatment of diabetic retinopathy［J］.J Control Release，2016，236：31-37.
［50］　ZHANG Y，SUN X，ICLI B，FEINBERG M W.Emerging roles for micrornas in diabetic microvascular disease：novel targets for therapy［J］.Endocr Rev，2017，38（2）：145-168.
［51］　KOWLURU R A，MISHRA M.Therapeutic targets for altering mitochondrial dysfunction associated with diabetic retinopathy［J］.Expert Opin Ther Targets，2018，22（3）：233-245.

相似文献/References:

[1]杜玮 刘子扬 周艳艳 雒雷鸣.糖尿病视网膜病变与血清胆红素水平的关系[J].眼科新进展,2012,32(5):000.
[2]杨红 阴正勤.眼球震颤的诊断与治疗研究进展[J].眼科新进展,2012,32(5):000.
[3]范松涛 卢建民.阿司匹林与糖尿病患者玻璃体出血以及玻璃体切割术疗效的相关性研究[J].眼科新进展,2012,32(11):000.
[4]李艳 李筱荣 袁佳琴 潘斌.糖尿病大鼠视网膜中VEGF、PEDF的表达与血-视网膜屏障损伤[J].眼科新进展,2013,33(1):000.
[5]李朝晖 崔治华 胡晓英 孟丽珠 张敬维.糖尿病视网膜病变激光面积与疗效的分析[J].眼科新进展,2013,33(2):000.
[6]史大领 王殿强.棘阿米巴性角膜炎的临床特点及诊断[J].眼科新进展,2013,33(6):000.
[7]冯冬梅 朱鸿 施彩虹.CXC趋化因子及其受体在糖尿病视网膜病变中的作用[J].眼科新进展,2013,33(6):000.
[8]牛淑玲.糖尿病视网膜病变患者HbAlc、FPG与血小板参数的变化及危险因素分析[J].眼科新进展,2013,33(7):000.
[9]毕春潮 王睿 王建洲 雷春灵 董晓娟 王小莉 薛晓辉.Ad-PEDF对糖尿病视网膜病变大鼠视网膜新生血管的抑制作用[J].眼科新进展,2013,33(8):000.
[10]杨萍 孙书明 李晓鹏.辛伐他汀对糖尿病视网膜病变和炎症因子的影响[J].眼科新进展,2013,33(8):000.
[11]邵毅,周琼.糖尿病视网膜病变诊治规范——2018年美国眼科学会临床指南解读[J].眼科新进展,2019,39(6):501.[doi:10.13389/j.cnki.rao.2019.0115]
　SHAO Yi,ZHOU Qiong.Interpretation of clinical guidelines for diabe-tic retinopathy of the American Academy of Ophthalmology 2018[J].Recent Advances in Ophthalmology,2019,39(12):501.[doi:10.13389/j.cnki.rao.2019.0115]

更新日期/Last Update: 2018-12-04